Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350723 | 1.00 | CCR5 (1.00) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5761955 | 0.99 | CCR5 (0.99) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5764570 | 0.99 | CCR5 (0.99) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5763414 | 0.96 | CCR5 (0.93) | CCR5KCNH2 | |
| SCHEMBL7550592 | 0.96 | CCR5 (0.92) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5764794 | 0.96 | CCR5 (0.92) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5762204 | 0.95 | CCR5 (0.91) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL5764951 | 0.95 | CCR5 (0.91) | CCR5KCNH2 | |
| SCHEMBL7552045 | 0.95 | CCR5 (0.91) | CCR5KCNH2 | |
| SCHEMBL7543614 | 0.95 | CCR5 (0.91) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090675-A1 | CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC CANCER | CytoDyn Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115003691-A | CCR5 binding agents for the treatment of CCR5 positive metastatic carcinoma | 西托戴恩股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114729023-A | anti-CCR5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by DNA damage chemotherapy | 西托戴恩股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220162327-A1 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | CYTODYN INC (US) | 2022-05-26 | — | — | US | disclosed |
| CN-114502594-A | Methods for treating or preventing cancer involving administration of anti-CCR5 receptor agents | 西托戴恩股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3947431-A1 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | CytoDyn Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021146323-A1 | CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC BREAST CANCER | CYTODYN INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210214448-A1 | CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER | CYTODYN INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3842066-A1 | USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE | CytoDyn Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-111886249-A | Screening method for identifying and treating HIV-1 infected patient subpopulations suitable for long-term anti-CCR 5 agent treatment | 西托戴恩股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| WO-2020206026-A1 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | CYTODYN INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| CN-111201034-A | Methods of treating or preventing graft versus host disease involving administration of anti-CCR 5 receptor agents | 西托戴恩股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| US-20190085086-A1 | SCREENING METHODS FOR IDENTIFYING AND TREATING HIV-1 INFECTED PATIENT SUB-POPULATIONS SUITABLE FOR LONG TERM ANTI-CCR5 AGENT THERAPY | CYTODYN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190016810-A1 | METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST DISEASE INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | CYTODYN INC. | 2019-01-17 | — | — | US | disclosed |
| EP-1910573-B1 | METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS | CYTODYN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-6593346-B2 | Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. | MERCK & CO. INC. | 2003-07-15 | — | — | US | disclosed |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-08-29 | — | — | US | disclosed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | CCR1, CCR3, CCR5 | CCR5 3/4885KCNH2 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.